CANSINOBIO (06185.HK): Td5cp Cleared for Trial in Children Aged 4-5

On 16 November 2026, CANSINOBIO (06185.HK) said the NMPA approved a trial of its Td5cp vaccine in children aged 4 to 5, widening the booster age range.

NewTimeSpace News: On 16 November 2026, CanSino Biologics Inc. (stock code: 6185) announced that the Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed (Td5cp) developed by the Company has obtained clinical trial approval from China's National Medical Products Administration to initiate the relevant clinical trial in people aged 4 to 5 years old.

The announcement noted that the incidence and severity of adverse reactions to full-dose co-purified DTaP vaccines tend to increase with both the number of doses and the age at vaccination, so reduced-dose component-purified Tdap vaccines are generally used overseas in place of DTaP for booster immunisation starting at 4 years old, with a lower incidence of adverse reactions owing to their lower pertussis and diphtheria antigen content.

The application proposes to expand the booster vaccination age for Td5cp from 6 years old to 4 to 6 years old, so as to stimulate immune memory and rapidly restore antibody levels to the protective range. This is expected to help fill the pre-school immunity gap and significantly reduce outbreak risks in childcare centres and primary schools, providing key support for building an all-age immunity barrier and controlling pertussis transmission.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.